Browsing Tag
AVA6000
26 posts
Is Avacta Therapeutics changing the rules of chemotherapy? Inside the Phase 1a findings that impressed ESMO
Avacta Therapeutics’ Phase 1a trial data shows faridoxorubicin’s tumor-targeted action and cardiac safety. Explore the implications for pre|CISION in solid tumors.
Can Avacta’s £16m fundraise extend its oncology momentum after 91% disease control rate?
Avacta raises ÂŁ16m to extend clinical runway into 2026 and reports 91% disease control in cancer trial. See why investors are watching AVCT closely.
Will Avacta’s pre|CISION platform turn its £3.25m bond repayment into a precision oncology breakthrough?
Avacta Group plc raises £3.25M to repay its convertible bond and extend clinical runway for its pre|CISION cancer drugs—find out what’s next.
Avacta Group advances Phase 1 trial of oncology drug candidate AVA6000
Avacta Group plc (AIM: AVCT), a prominent life sciences company, has achieved a significant milestone in its Phase…
Avacta Group reports promising early results for Phase 1a study of AVA6000
Avacta Group plc (AIM: AVCT), a leading life sciences company dedicated to developing innovative oncology drugs and powerful…
Avacta Group progresses to final cohort in Phase 1a study of AVA6000
Avacta Group plc (AIM: AVCT), a leader in the life sciences sector specializing in innovative oncology drugs and…